BioLineRx Ltd.
롱
업데이트됨

BLRX-BREAKOUT-UPDATE

389
BLRX had a strong rally today and it's just getting started.

In the related idea my price target was $1.34.

Today's high was $1.78

Check out the weekly chart:

스냅샷

Photo Finish.

$1.34 was 1.618 extension level from Waves 1 & 2.

Since the price-action broke $1.34 we will have an extended 3rd wave.

I expect a very strong rally tomorrow, I will update in the morning before the open to confirm.

Target is hard to predict since its impossible to know what level extending waves will terminate.

I will keep a close eye on the price-action.

Will update.

-AB






노트
As expected, a very strong rally today!
노트
스냅샷
노트
We got a big runway...
노트
Reminder this is a WEEKLY chart...

Meaning this move is far from over...
노트
스냅샷
노트
Buckle up!
노트
스냅샷
노트
Target $2.24 (Sell Half)

Trade Price: 1.049
노트
스냅샷
노트
스냅샷
노트
Bull Flag
노트
BLRX will rally again tomorrow.
노트
스냅샷
노트
BLRX is about to rally again...
노트
BLRX continued to consolidate today.

Staying the course...
노트
스냅샷
노트
스냅샷
노트
Near-Term Target: $2.13
노트
스냅샷
노트
Primary Wave 1 Complete
노트
스냅샷
노트
03:21 PM EDT, 10/22/2018 (MT Newswires) -- Oppenheimer has kept its outperform rating on BioLineRx (BLRX) with a price target of $3, betting on BL-8040's commercial opportunity as a stem cell mobilizer after top-line data from the COMBAT/KEYNOTE-202 trial of BL-8040 in combination with pembrolizumab in advanced pancreatic cancer showed modest response rate.
"Given the combination's favorable safety profile, BioLineRx and Merck (MRK) are testing a triplet combination including chemotherapy in an effort to increase response rate," analyst Mark Breidenbach said in a note.
"While we believe the triplet combination is worth testing, our valuation of BioLineRx still remains focused on BL-8040's commercial opportunity as a stem cell mobilizer."
노트
스냅샷
노트
스냅샷
노트
Breakout Imminent
노트
스냅샷

면책사항

해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.